Fig. 1From: Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritisThe pooling strategy. Data from Study 1 (NCT02697773) [14] dose-titration group (tanezumab 2.5 mg at baseline, tanezumab 5 mg at week 8) were pooled with the Study 2 (NCT02709486) [15] tanezumab 5 mg group for analyses at week 16. RCT, randomized controlled trial; SC, subcutaneousBack to article page